BBO 10203
Alternative Names: BBO-10203; PI3K alpha:RAS breaker - BridgeBio PharmaLatest Information Update: 09 May 2024
At a glance
- Originator BridgeBio Pharma
- Class Antineoplastics; Small molecules
- Mechanism of Action Phosphatidylinositol 3 kinase alpha inhibitors; Ras signal transduction pathway inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Solid tumours
Most Recent Events
- 02 May 2024 BridgeBio Pharma plans to file an IND application in Solid tumours in the second quarter of 2024
- 02 May 2024 BridgeBio Pharma plans a clinical trial for Solid tumours (unspecified) in 2024
- 05 Dec 2023 Pharmacodynamics data from the preclinical studies Solid tumours presented at the 46th Annual San Antonio Breast Cancer Symposium (SABCS-2023)